Live Breaking News & Updates on Mark garzotto

Stay informed with the latest breaking news from Mark garzotto on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Mark garzotto and stay connected to the pulse of your community

Biweekly Cabazitaxel for mCRPC Safe for Men Aged 65+ - Renal and Urology News

Findings from the phase 3 randomized CABASTY clinical trial “may be practice changing,” investigators reported. Biweekly vs triweekly cabazitaxel for mCRPC in men aged 65 years or older has similar efficacy but is associated with a lower risk for neutropenia and/or neutropenic complications.

Massachusetts , United-states , France , Portland , Oregon , Paris , France-general- , Boston , Mark-garzotto , Douglas-dahl , Portland-va-medical-center , Division-of-urologic-oncology-at-massachusetts

Cybersecurity experts weigh in on data breach impacting Oregonians

Cybersecurity experts weigh in on data breach impacting Oregonians
kval.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kval.com Daily Mail and Mail on Sunday newspapers.

Oregon , United-states , Oregon-department-of-transportation , Washington , Portland , Chris-berge , Mark-garzotto , Washington-department-of-licensing , Experian , Transunion , Equifax , Oregon-department

Cybersecurity experts weigh in on data breach impacting Oregonians

Cybersecurity experts weigh in on data breach impacting Oregonians
kpic.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kpic.com Daily Mail and Mail on Sunday newspapers.

Oregon , United-states , Oregon-department-of-transportation , Portland , Washington , Chris-berge , Mark-garzotto , Equifax , Experian , Transunion , Washington-department-of-licensing , Oregon-department

Cybersecurity experts weigh in on data breach impacting Oregonians

Cybersecurity experts weigh in on data breach impacting Oregonians
nbc16.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nbc16.com Daily Mail and Mail on Sunday newspapers.

Portland , Oregon , United-states , Washington , Oregon-department-of-transportation , Chris-berge , Mark-garzotto , Experian , Equifax , Washington-department-of-licensing , Transunion , Oregon-department

Extended LND During Radical Cystectomy Offers No Overall Survival Edge

Radical cystectomy with extended vs standard lymph node dissection (LND) offers no advantage for tumor recurrence or overall survival.

Oregon , United-states , Italy , Germany , Milan , Lombardia , New-haven , Connecticut , Arnulf-stenzl , Mark-garzotto , Joseph-brito , Oregon-health-science-university-in-portland

EPO No Help for Erectile Dysfunction After Radical Prostatectomy

email article
Perioperative treatment to preserve nerve function did not significantly improve erectile function after surgery for prostate cancer, a randomized, placebo-controlled study showed.
Six months after radical prostatectomy, patients treated with erythropoietin (EPO) or placebo had similar scores on a validated scale of erectile function. In fact, the median score favored the placebo group (19 vs 14). Investigators also found no significant difference between groups at 3, 9, and 12 months. Adjustment for nerve-sparing surgery, which was associated with recovery of erectile function, had minimal effect on analyses of primary and secondary endpoints.
The EPO group had significantly higher hemoglobin levels during treatment, consistent with administration of EPO, reported Hiten D. Patel, MD, of Johns Hopkins School of Medicine in Baltimore, and co-authors in the

Oregon , United-states , Charles-bankhead , Hitend-patel , Mark-garzotto , Poones-shoureshi , Oregon-health-science-university-in-portland , Johns-hopkins-school-of-medicine , International-index-of-erectile-function , Johns-hopkins-school , Oregon-health , Science-university

PI3K/AKT/mTOR Inhibitors for Prostate Cancer – Finally Hints of a Breakthrough

PI3K/AKT/mTOR Inhibitors for Prostate Cancer – Finally Hints of a Breakthrough
Published 05 January 2021
Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway has been strongly linked with prostate cancer progression and metastatic potential.
1 Loss of the inhibitory phosphatase, PTEN, leading to hyperactivation of PI3K/AKT/mTOR oncogenic signaling, occurs in 40-50% of metastatic castration-resistant prostate cancer.
1,2 Not surprising is the fact that PTEN loss in patients with metastatic castration-resistant prostate cancer is associated with a worse prognosis and less benefit from androgen receptor (AR) blockade.
3 Likewise, PTEN loss and subsequent Akt activation confer radiation

Washington , United-states , Fred-hutchinson-cancer-research-center , University-of-washington , Seattle , Yunfeng-li , Shunyou-wang , Evany-shi , Nicholast-ingolia , Seema-plaisier , Vivekk-arora , Ratnab-ray